Nasodren: strong scientific support
- Nasodren is effective and safe for the treatment of patients with ARS assessed subjectively and objectively.
- The specific symptom of facial pain/pressure significantly improved after 5 - 7 days treatment with CE. This is important since facial pain/pressure is undoubtedly one of the most severe symptoms affecting the patient’s quality of life in ARS.
- Endoscopic evaluation showed that mucus oedema/nasal obstruction improved significantly with CE. Improvement (defined as a sum of endoscopy scores of 0) was significantly higher with CE than placebo at the end of the study.
- Both patients and investigators reported significantly greater treatment satisfaction with CE than placebo
- CE is a safe product for the treatment of ARS
In March, another unique and impressive study was accepted for publication in The Laryngoscope, (organ of the American Laryngological, Rhinological and Otological Society): “An exploratory Trial of Cyclamen Europaeum Extract for Acute Rhinosinusitis” by J. Ponikau et al.
The key messages learnt from this study are:
In patients with Acute Rhinosinusitis, Cyclamen extract (Nasodren / Sinuforte):
- Improves objective outcomes compared to placebo
- Produces a clinically relevant symptoms improvement
- Is the only product marketed for Rhinosinusitis that has been tested in this way (CT); other products, such as corticosteroids, antibiotics or decongestants, measure only symptomatic improvement.
References:
Pfaar O, Mullol J, Anders C, Hormann K, Klimek L. Cyclamen europaeum nasal spray, a novel phytotherapeutic product for the management of acute Rhinosinusitis: a randomized double-blind, placebo-controlled trial. Rhinology. 2012 Mar;50(1):37-44. PMID: 22469604
Ponikau J, Hamilos D, Barreto A, Cecil J, Jones S, Manthei S. An exploratory trial of Cyclamen europaeum extract for acute Rhinosinusitis. Accepted for publication Laryngoscope, March, 2012. PMID: 22675486